Corrigendum to “Asundexian in atrial fibrillation – Can pharmacodynamic data explain the failure?” [Thromb. Res. 236 (2024) 236–239 TR_8963]

Corrigendum to “Asundexian in atrial fibrillation – Can pharmacodynamic data explain the failure?” [Thromb. Res. 236 (2024) 236–239 TR_8963]

Julie Vassart a), Marie Didembourg a), Laure Morimont a) b), Clotilde Brisbois b), Laurent Jamart c), Aurélien Lebreton d), François Mullier e) f), Nathalie Donis b), Julien Favresse a) g), Jean-Michel Dogné a), Jonathan Douxfils a) b) d)

a-Clinical Pharmacology and Toxicology Research Unit (URPC), Faculty of Medicine, Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium
b-QUALIresearch, QUALIblood s.a., Namur, Belgium
c-Service de cardiologie interventionnelle, Centre Hospitalier Régional Sambre et Meuse (CHRSM), Namur, Belgium
d-Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France
e-Namur Thrombosis and Hemostasis Center (NTHC), CHU UCL NAMUR, Université catholique de Louvain, Belgium
f-Institut de Recherche Expérimentale et Clinique (IREC), Pôle Mont, Université catholique de Louvain, Yvoir, Belgium
g-Department of Clinical Biology, Clinique Saint-Luc Bouge (SLBO), Bouge, Belgium

The authors regret that the final concentrations of tissue factor and phospholipids reported for the thrombin generation assay are incorrect. This information can be found on page 236, in the following paragraph: “Three different reagents were used: PPP Reagent Low (1 pM tissue factor (TF) [0.16 pM in final concentration]; 4 μM phospholipids (PL)), PPP Reagent (5 pM TF [0.80 pM in final concentration]; 4 μM phospholipids) and PPP Reagent High (20 pM TF [3.2 pM in final concentration]; 4 μM phospholipids). A fourth reagent was prepared by diluting the PPP Reagent Low 10-fold (0.1 pM TF [0.016 pM in final concentration]; 0.4 μM phospholipids).”.

The correct version of this paragraph is: “Three different reagents were used: PPP Reagent Low (final concentrations: 1 pM tissue factor (TF), 4 μM phospholipids), PPP Reagent (5 pM TF, 4 μM phospholipids) and PPP Reagent High (20 pM TF, 4 μM phospholipids). A fourth reagent was prepared by diluting the PPP Reagent Low 10-fold (0.1 pM TF, 0.4 μM phospholipids)”.

The authors would like to apologise for any inconvenience caused.